Rohto Pharmaceutical Co., Ltd.

Japan

Back to Profile

1-100 of 374 for Rohto Pharmaceutical Co., Ltd. Sort by
Query
Excluding Subsidiaries
Aggregations Reset Report
IP Type
        Patent 305
        Trademark 69
Jurisdiction
        World 268
        United States 73
        Europe 19
        Canada 14
Date
New (last 4 weeks) 4
2025 June (MTD) 2
2025 May 2
2025 April 4
2025 March 6
See more
IPC Class
A61P 27/02 - Ophthalmic agents 71
A61K 9/08 - Solutions 64
A61Q 19/00 - Preparations for care of the skin 47
A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers 45
A61P 43/00 - Drugs for specific purposes, not provided for in groups 37
See more
NICE Class
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations 46
05 - Pharmaceutical, veterinary and sanitary products 30
10 - Medical apparatus and instruments 7
29 - Meat, dairy products, prepared or preserved foods 4
30 - Basic staples, tea, coffee, baked goods and confectionery 3
See more
Status
Pending 29
Registered / In Force 345
  1     2     3     4        Next Page

1.

COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD

      
Application Number 18832341
Status Pending
Filing Date 2023-01-20
First Publication Date 2025-06-05
Owner
  • HIROSHIMA UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimada, Masayuki
  • Umehara, Takashi
  • Ishikawa, Noriyasu
  • Takijiri, Takashi

Abstract

The purpose of the present invention is to provide spermatozoa having high motility. The present invention is a composition for treating sperm that comprises a mesenchymal stem cell culture supernatant. The composition for spermatozoa treatment of the present invention is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Furthermore, mesenchymal stem cells in the mesenchymal stem cell culture supernatant comprised in the composition for treating sperm are preferably derived from adipose tissue, derived from umbilical cord tissue, or derived from bone marrow tissue.

IPC Classes  ?

  • C12N 5/076 - Sperm cellsSpermatogonia
  • C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

2.

AGENTS FOR PROMOTING OR IMPROVING DECIDUALIZATION OF ENDOMETRIUM

      
Application Number JP2024042312
Publication Number 2025/116006
Status In Force
Filing Date 2024-11-29
Publication Date 2025-06-05
Owner
  • HIROSHIMA UNIVERSITY (Japan)
  • TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimada,masayuki
  • Kusama,kazuya

Abstract

Provided is a preparation with which it is possible to promote normal decidualization of the endometrium. An agent for promoting or improving decidualization of the endometrium, the agent containing an effective amount of pyrroloquinoline quinone or a salt thereof, is prepared. Furthermore, an agent for promoting or improving cell fusion, the agent containing an effective amount of pyrroloquinoline quinone or a salt thereof, is prepared.

IPC Classes  ?

  • A61K 31/475 - QuinolinesIsoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
  • A61P 15/00 - Drugs for genital or sexual disordersContraceptives
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

3.

METHOD FOR PREPARING CELLS FOR TREATING DISEASES, METHOD FOR PROMOTING MIGRATION ABILITY OF CELLS, METHOD FOR PROMOTING PROLIFERATION ABILITY OF CELLS, AND CELLS OBTAINED BY THESE METHODS

      
Application Number 18834375
Status Pending
Filing Date 2023-01-26
First Publication Date 2025-05-08
Owner
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
  • SONIKURE HOLDINGS LIMITED (China)
Inventor
  • Kurogi, Hikari
  • Arya, Smriti
  • Choi, Ka Ming
  • Lo, Hau Yi Paulisally
  • Suen, Wai Leung Langston
  • Lau, Wai Ki
  • Armstrong, Jamison Thomas

Abstract

An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.

IPC Classes  ?

  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
  • C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

4.

COMPOSITION FOR TREATING IMMATURE EGG AND/OR EMBRYO (FERTILIZED EGG)

      
Application Number JP2024037680
Publication Number 2025/094776
Status In Force
Filing Date 2024-10-23
Publication Date 2025-05-08
Owner
  • UNIVERSITY PUBLIC CORPORATION OSAKA (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Hashimoto Shu
  • Kitaji Hideki
  • Takijiri Takashi

Abstract

The purpose of the present invention is to provide a culture medium for immature eggs that is excellent in quality and safety and that is capable of efficiently maturing immature eggs with respect to immature eggs for vitro maturation-in vitro fertilization-embryo transfer method (IVM-IVF). The present invention is a composition that is for treating immature eggs and/or embryos (fertilized eggs) and that contains a serum-free mesenchymal stem cell culture medium. The treatment composition is suitably used as an immature egg culture agent, an embryo (fertilized egg) culture agent, an implantation adjuvant, an embryo transfer liquid or an implantation rate improver.

IPC Classes  ?

5.

Melty Cream Lip

      
Application Number 239483000
Status Pending
Filing Date 2025-04-24
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations

Goods & Services

(1) Abrasive cloth and paper; adhesives for affixing false eyelashes; adhesives for affixing false hair; after sun moisturisers; air fragrancing preparations; anti-perspirants; antiperspirant soap; astringents for cosmetic purposes; baby lotion; baby powder; bath foam; bath salts; beauty masks; beauty serums; body lotions; body washes; breath freshening sprays; breath freshening strips; cleansers for intimate personal hygiene purposes, non-medicated; cleansing milk for toilet purposes; cloths impregnated with a detergent for cleaning; cosmetic creams; cosmetic kits; cosmetic preparations for skin care; cosmetic preparations for slimming purposes; cosmetics; cotton sticks for cosmetic purposes; creams for leather; dentifrices; deodorant soap; deodorants for human beings; depilatories; fabric softeners for laundry use; face powder; facial concealer; facial moisturizers; facial soaps; facial washes; false eyelashes; false nails; fragrances; furniture polish; hair care creams; hair coloring preparations; hair lotions; hair moisturizers; hair nourishers for cosmetic purposes; hair setting preparations; hand creams; hand soap; incense; laundry bleach; laundry starch; lip cream; lip glosses; lipsticks; lotions for cosmetic purposes; make-up preparations; make-up removing creams; make-up removing preparations; massage oil, non-medicated; milk for cosmetic purposes; moisturizing creams; non-medicated lip balms; paint stripping preparations; polishing wax; room fragrances; rust removing preparations; shampoos; shaving creams; shoe polish and creams; skin lotions; skin whitening creams; sunscreen preparations; tissues impregnated with cosmetic lotions (2) Soaps for cosmetic purposes; Non-medicated soap for acne; Beauty care preparations in gel foam; Foaming beauty care preparations; Lotion-type beauty care preparations; Emulsion-type beauty care preparations; Oil-based beauty care preparations; Body Soap;

6.

Melty Cream Lip

      
Application Number 239269000
Status Pending
Filing Date 2025-04-16
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations

Goods & Services

(1) Abrasive cloth and paper; adhesives for affixing false eyelashes; adhesives for affixing false hair; after sun moisturisers; air fragrancing preparations; anti-perspirants; antiperspirant soap; astringents for cosmetic purposes; baby lotion; baby powder; bath foam; bath salts; beauty masks; beauty serums; body lotions; body washes; breath freshening sprays; breath freshening strips; cleansers for intimate personal hygiene purposes, non-medicated; cleansing milk for toilet purposes; cloths impregnated with a detergent for cleaning; cosmetic creams; cosmetic kits; cosmetic preparations for skin care; cosmetic preparations for slimming purposes; cosmetics; cotton sticks for cosmetic purposes; creams for leather; dentifrices; deodorant soap; deodorants for human beings; depilatories; fabric softeners for laundry use; face powder; facial concealer; facial washes; false eyelashes; false nails; fragrances; furniture polish; hair care creams; hair coloring preparations; hair lotions; hair moisturizers; hair nourishers for cosmetic purposes; hair setting preparations; hand creams; hand soap; incense; laundry bleach; laundry starch; lip cream; lip glosses; lipsticks; lotions for cosmetic purposes; make-up preparations; make-up removing creams; make-up removing preparations; massage oil, non-medicated; milk for cosmetic purposes; non-medicated lip balms; non-medicated mouth washes; paint stripping preparations; polishing wax; room fragrances; rust removing preparations; shampoos; shaving creams; shoe polish and creams; skin lotions; skin whitening creams; sunscreen preparations; tissues impregnated with cosmetic lotions (2) Soaps for cosmetic purposes; Non-medicated soap for acnes;

7.

COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD

      
Application Number 18832346
Status Pending
Filing Date 2023-01-20
First Publication Date 2025-04-10
Owner
  • HIROSHIMA UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimada, Masayuki
  • Umehara, Takashi
  • Ishikawa, Noriyasu
  • Takijiri, Takashi

Abstract

The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for treating sperm that comprises medium for mesenchymal stem cells. This composition for treating sperm is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for treating sperm is preferably a serum-free medium.

IPC Classes  ?

8.

COMPOSITION FOR MAINTAINING OR INCREASING FIBROUS STRUCTURAL PROTEIN

      
Application Number JP2024034653
Publication Number 2025/070726
Status In Force
Filing Date 2024-09-27
Publication Date 2025-04-03
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Yamada,kotaro
  • Soejima,yoshiomi
  • Nakahara,ken
  • Taira,toshio
  • Matsumoto,nozomi
  • Mizutani,kaoru

Abstract

The purpose of the present invention is to provide a preparation that is effective for maintaining or increasing a hair fibrous structural protein. Provided are a composition for maintaining or increasing a fibrous structural protein, a composition for maintaining or increasing skin elasticity, a composition for improving hair quality, and a composition for promoting the production of collagen, elastin, or hyaluronic acid, wherein each of the compositions contains a culture supernatant of microalgae and/or extracellular vesicles of microalgae.

IPC Classes  ?

  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A61K 8/9706 - Algae
  • A61K 8/9722 - Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
  • A61K 36/02 - Algae
  • A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
  • A61P 17/00 - Drugs for dermatological disorders
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • A61Q 19/00 - Preparations for care of the skin
  • C12N 1/12 - Unicellular algaeCulture media therefor

9.

AQUEOUS COMPOSITION

      
Application Number JP2024032940
Publication Number 2025/063144
Status In Force
Filing Date 2024-09-13
Publication Date 2025-03-27
Owner
  • TSUBOTA LABORATORY, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Nishimoto Akinori

Abstract

This aqueous composition contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and has a pH of 6.0-9.0. The aqueous composition is housed in a dispensing container having a filter containing a hydrophilic material.

IPC Classes  ?

  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
  • A61K 9/08 - Solutions
  • A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
  • A61P 27/02 - Ophthalmic agents
  • A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

10.

NOVEL TRIAZINE DERIVATIVE AND SALT THEREOF, AND ULTRAVIOLET ABSORBENT, EXTERNAL SKIN AGENT, AND COATING COMPOSITION USING SAME

      
Application Number JP2023033152
Publication Number 2025/057289
Status In Force
Filing Date 2023-09-12
Publication Date 2025-03-20
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimizu,takashi
  • Hayashi,yuya
  • Kubo,ozora

Abstract

The present invention relates to providing a novel compound, specifically a 1,3,5-triazine derivative and salt thereof, which has a suitable ultraviolet absorption action, and to an ultraviolet absorbent and external skin agent using the same. The present invention is the 1,3,5-triazine derivative or salt thereof represented by general formula (I), etc. (In the general formula, G1, G2, and G3each independently represent hydrogen, a straight or branched chain alkyl group, etc. having 1-12 carbon atoms which may be substituted, or -X-Z-Y. However, at least two of G1, G2, and G3may be -X-Z-Y, which may be identical or different from each other. X is O, N, or S. Y is a sulfonic acid group, a hydroxyl group, or a carboxyl group, etc., or a group corresponding to a salt thereof. Z is a straight or branched chain alkyl group, etc. having 1-8 carbon atoms. R1, R2, and R3 each independently represent a straight or branched chain alkyl group, etc. having 1-4 carbon atoms, and l, m, and n each independently represent an integer from 0 to 4.)

IPC Classes  ?

11.

CLEANSING COMPOSITION AND METHOD FOR REMOVING AGING ODOR

      
Application Number JP2024031369
Publication Number 2025/053092
Status In Force
Filing Date 2024-08-30
Publication Date 2025-03-13
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Sawa Kazuhiro
  • Otani Yusuke

Abstract

Provided are a cleansing composition and the like having excellent sebum cleansing properties. Specifically provided are a cleansing composition comprising components (A), (B) and (C) as mentioned below, a cleaning composition for deodorant purposes, and a method for removing an aging odor by cleansing using a cleansing composition. (A) An anionic cleansing component. (B): A component (B1) and/or a component (B2) as mentioned below. (B1) A monoester of a C6-12 fatty acid and a C1-6 polyhydric alcohol. (B2) At least one component selected from the group consisting of fatty acid alkanolamides, coconut oil fatty acid polyoxyethylene glyceryls, and polyoxyethylene alkyl ethers. (C) A water-soluble polymer.

IPC Classes  ?

  • A61K 8/36 - Carboxylic acidsSalts or anhydrides thereof
  • A61K 8/37 - Esters of carboxylic acids
  • A61K 8/39 - Derivatives containing from 2 to 10 oxyalkylene groups
  • A61K 8/42 - Amides
  • A61K 8/73 - Polysaccharides
  • A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K 8/86 - Polyethers
  • A61Q 5/02 - Preparations for cleaning the hair
  • A61Q 15/00 - Anti-perspirants or body deodorants
  • A61Q 19/10 - Washing or bathing preparations
  • C11D 1/02 - Anionic compounds
  • C11D 1/04 - Carboxylic acids or salts thereof
  • C11D 1/52 - Carboxylic amides, alkylolamides or imides
  • C11D 1/74 - Carboxylates or sulfonates of polyoxyalkylene glycols
  • C11D 3/20 - Organic compounds containing oxygen
  • C11D 3/37 - Polymers

12.

OPHTHALMIC COMPOSITION

      
Application Number JP2024031809
Publication Number 2025/053197
Status In Force
Filing Date 2024-09-05
Publication Date 2025-03-13
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Nakata Atsuko

Abstract

The present invention pertains to an ophthalmic composition containing (A) at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 1000 to 20000 and a salt thereof, and (B) a fat-soluble component.

IPC Classes  ?

  • A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
  • A61K 9/08 - Solutions
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
  • A61P 27/02 - Ophthalmic agents

13.

OPHTHALMIC COMPOSITION

      
Application Number JP2024031846
Publication Number 2025/053216
Status In Force
Filing Date 2024-09-05
Publication Date 2025-03-13
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Nakata Atsuko

Abstract

The present invention pertains to an ophthalmic composition containing (A) at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 1000 to 20000 and a salt thereof, and (B) at least one selected from the group consisting of water-soluble vitamins, amino acids, and salts thereof.

IPC Classes  ?

  • A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
  • A61K 9/08 - Solutions
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61P 27/02 - Ophthalmic agents

14.

EXTERNAL-USE COMPOSITION AND METHOD FOR ENHANCING FRAGRANCE OF SAME

      
Application Number JP2024028586
Publication Number 2025/052869
Status In Force
Filing Date 2024-08-08
Publication Date 2025-03-13
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Seki Momoka
  • Yamashita Rikako

Abstract

The purpose of the present invention is to provide an external-use composition with which aroma is maintained for a long period of time after application to the skin. Another purpose of the present invention is to provide a method with which it is possible, in relation to an external-use composition, to provide sufficient fragrance after application to the skin, and to maintain the fragrance for a long period of time. The present invention is an external-use composition containing (A) a hydroxy fatty acid or a salt thereof having 10 or more carbon atoms and a hydroxy group at the 4-position or 5-position, and (B) one or more components selected from the group consisting of (b-1) 1-6-valent alkyl alcohols, (b-2) amphiphilic esters, (b-3) phenol derivatives, and (b-4) cationized polymers.

IPC Classes  ?

  • A61K 8/34 - Alcohols
  • A61K 8/39 - Derivatives containing from 2 to 10 oxyalkylene groups
  • A61K 8/73 - Polysaccharides
  • A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
  • A61Q 5/02 - Preparations for cleaning the hair
  • A61Q 5/06 - Preparations for styling the hair, e.g. by temporary shaping or colouring
  • A61Q 5/12 - Preparations containing hair conditioners
  • A61Q 13/00 - Formulations or additives for perfume preparations
  • A61Q 15/00 - Anti-perspirants or body deodorants
  • A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
  • A61Q 19/00 - Preparations for care of the skin
  • A61Q 19/10 - Washing or bathing preparations

15.

AGENT FOR ACTIVATING HAIR DERMAL PAPILLA CELLS

      
Application Number JP2024029989
Publication Number 2025/041852
Status In Force
Filing Date 2024-08-23
Publication Date 2025-02-27
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Yamada,kotaro
  • Soejima,yoshiomi
  • Nakahara,ken

Abstract

The purpose of the present invention is to provide a pharmaceutical preparation that effectively activates hair dermal papilla cells. Provided is a composition for activating hair dermal papilla cells, a composition for promoting hair growth or for hair restoration, a composition for improving hair quality, and a composition for promoting production of FGF-2, FGF-7, or VEGF, the compositions containing microalgae culture supernatant and/or microalgae extracellular vesicle.

IPC Classes  ?

  • A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
  • A61K 8/9706 - Algae
  • A61K 36/02 - Algae
  • A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • A61Q 7/00 - Preparations for affecting hair growth
  • C12N 1/12 - Unicellular algaeCulture media therefor

16.

INTERNAL COMPOSITION FOR LIPOLYSIS AND/OR WEIGHT LOSS, METHOD FOR DETERMINING EFFECTIVENESS, AND INDEX FOR QUALITY OF PLANT EXTRACT

      
Application Number JP2024028767
Publication Number 2025/037604
Status In Force
Filing Date 2024-08-09
Publication Date 2025-02-20
Owner
  • MG PHARMA INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ishido Keiichi
  • Sasakawa Yuka
  • Sumida Yasuo
  • Tsukamoto Kosei

Abstract

The present invention provides a novel preparation which has an excellent lipolysis-promoting effect, an excellent visceral fat and body fat loss effect, an excellent weight loss effect, and an excellent BMI improvement effect. Another purpose of the present invention is to provide a novel preparation which has an excellent insulin resistance amelioration effect, an excellent cholesterol level reduction effect, and the like. The present invention is an internal composition which contains glyasperin B and which is used for at least one of lipolysis, fat burning, fat consumption support, BMI improvement, BMI reduction support, abdominal fat loss, visceral fat loss, body fat loss, waist circumference reduction, insulin resistance amelioration, and LDL cholesterol level reduction. The internal composition according to the present invention is preferably used by adults who have a BMI of at least 23 kg/m2but less than 30 kg/m2and adults who have a visceral fat area of at least 100 cm2.

IPC Classes  ?

  • A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A61K 36/484 - Glycyrrhiza (licorice)
  • A61P 3/04 - AnorexiantsAntiobesity agents
  • A61P 3/06 - Antihyperlipidemics
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

17.

OIL-BASED SOLID COMPOSITION FOR EXTERNAL USE

      
Application Number 18709382
Status Pending
Filing Date 2022-11-22
First Publication Date 2025-02-06
Owner
  • THE MENTHOLATUM COMPANY (USA)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Kawaguchi, Yoshiaki

Abstract

To provide an oil-based solid composition for external use having excellent stability. An oil-based solid composition for external use is prepared that comprises: (A) an oily component with a melting point of 55° C. or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer.

IPC Classes  ?

  • A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K 8/34 - Alcohols
  • A61K 8/63 - SteroidsDerivatives thereof
  • A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K 8/92 - Oils, fats or waxesDerivatives thereof, e.g. hydrogenation products
  • A61Q 19/00 - Preparations for care of the skin

18.

EMULSION COMPOSITION

      
Application Number JP2024026434
Publication Number 2025/028360
Status In Force
Filing Date 2024-07-24
Publication Date 2025-02-06
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kodama,takashi
  • Nakada,taiki

Abstract

Provided is a stable emulsion composition. Prepared is an emulsion composition comprising: (A) an oily component; (B) 40% by mass or more of one or more selected from the group consisting of polyhydric alcohols having 3 to 5 carbon atoms and polyethylene glycol; (C) one or more selected from the group consisting of polyacrylamide compounds and polyvinylpyrrolidone; (D) 0%-15% by mass of water; and (E) at least one selected from PEG -20 phytosterol, polyoxyethylene arachyl ether, glyceryl behenate, and polyglyceryl-6 octastearate.

IPC Classes  ?

  • A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K 8/06 - Emulsions
  • A61K 8/34 - Alcohols
  • A61K 8/37 - Esters of carboxylic acids
  • A61K 8/39 - Derivatives containing from 2 to 10 oxyalkylene groups
  • A61K 8/63 - SteroidsDerivatives thereof
  • A61K 8/86 - Polyethers
  • A61Q 19/00 - Preparations for care of the skin

19.

OPHTHALMOLOGICAL COMPOSITION

      
Application Number 18695745
Status Pending
Filing Date 2022-09-30
First Publication Date 2024-11-28
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Morikawa, Takuto
  • Matsumoto, Sachiko
  • Matsuki, Rie

Abstract

The present invention relates to an ophthalmological composition containing zinc chloride (A) and a polyvinyl-based polymer compound (B).

IPC Classes  ?

  • A61K 33/30 - ZincCompounds thereof
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/79 - Polymers of vinyl pyrrolidone
  • A61P 27/04 - Artificial tearsIrrigation solutions

20.

ROHTO

      
Application Number 1825311
Status Registered
Filing Date 2024-06-10
Registration Date 2024-06-10
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 10 - Medical apparatus and instruments
  • 32 - Beers; non-alcoholic beverages
  • 35 - Advertising and business services
  • 43 - Food and drink services, temporary accommodation
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Chemicals; glue and adhesives for industrial purposes; plant growth regulating preparations; fertilizers; ceramic glazings; priming putty; higher fatty acids; alkaline metals; alkaline-earth metals; non-metallic minerals; chemical compositions for developing and printing photographs; reagent paper [not for medical purposes]; artificial sweeteners for industrial purposes; flour and starch for industrial purposes; plastics [raw materials]; groundwood pulp or chemical pulps for manufacturing purposes; yeast nutrients for industrial purposes; yeast for scientific purposes; microorganisms for scientific, industrial or agricultural use; culture medium for photosynthetic bacteria; cultured microorganisms (not for medical and veterinary use); bacterial preparations, other than for medical and veterinary use; bacteriological preparations for acetification; bacteriological preparations other than for medical and veterinary use; gram-negative bacteria, escherichia coli strains, and other cultured microorganisms (not for medical and veterinary use); cellulolytic microorganisms (not for medical and veterinary use). Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; laundry starch; seaweed gelatine for laundry use [funori]; adhesives for affixing false eyelashes; breath freshening preparations; deodorants for animals; paint stripping preparations; shoe cream; shoe black [shoe polish]; polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumes and flavourings for beverages [essential oils]; perfumes and food flavourings [essential oils]; incense; abrasive paper [sandpaper]; abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes. Pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination; stem cells for medical, pharmaceutical or veterinary use; stem cells for regenerative medicine, medicine or veterinary use; stem cells (only for medical and veterinary use); diagnostic reagents for clinical or medical laboratory use; diagnostic media for bacteriological cultures; microorganism culture media for medical use; cell culture media for medical or veterinary use; serums; serotherapeutic medicines; fumigants [only for agricultural purposes]; fungicides [only for agricultural purposes]; rodenticides [only for agricultural purposes]; insecticides [only for agricultural purposes]; herbicides [weedkillers]; insect-repellents [only for agricultural purposes]; antiseptics [only for agricultural purposes]. Finger guards for medical purposes; sanitary masks; pacifiers for babies; ice bag pillows for medical purposes; triangular bandages; support bandages; surgical catguts; feeding cups for medical purposes; dropping pipettes for medical purposes; teats; medical ice bags; medical ice bag holders; baby bottles; nursing bottles; contraceptives, non-chemical; artificial tympanic membranes; prosthetics or fillings materials, not for dental use; ear plugs for swimmers; ear plugs for sleeping; ear plugs for soundproofing; facial equipment using ultrasonic waves for commercial use; esthetic massage apparatus for commercial use; medical apparatus and instruments; facial equipment using ultrasonic waves for household purposes; electric massage apparatus for household purposes; gloves for medical purposes; urinals for medical purposes; bed pans; ear picks. Beer; carbonated drinks [refreshing beverages]; fruit juices; vegetable juices [beverages]; extracts of hops for making beer; whey beverages. Advertising and publicity services; promoting the goods and services of others through the administration of sales and promotional incentive schemes involving trading stamps; business management analysis or business consultancy; business management; marketing research or analysis; providing information concerning commercial sales; employment agency services; auctioneering; import-export agencies; arranging newspaper subscriptions; shorthand services; transcription; document reproduction; office functions, namely filing, in particular documents or magnetic tapes; compilation of information into computer databases; providing business assistance to others in the operation of data processing apparatus namely, computers, typewriters, telex machines and other similar office machines; reception services for visitors in buildings [office functions]; publicity material rental; rental of photocopying machines; providing commercial information and advice for consumers in the choice of products and services; providing employment information; providing information about newspaper articles being news clipping services; rental of vending machines; retail services or wholesale services for foods and beverages; retail services or wholesale services for carbonated drinks [refreshing beverages] and non-alcoholic fruit juice beverages; retail services or wholesale services for tea, coffee and cocoa; retail services or wholesale services for processed food; retail or wholesale of pharmaceutical, veterinary, sanitary preparations and medical aids; retail services or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies; retail services or wholesale services for cosmetics, toiletries, dentifrices, soaps and detergents. Providing temporary accommodation; accommodation bureaux services [hotels, boarding houses]; providing foods and beverages; boarding for animals; preschooler and infant care at daycare centers; retirement home; rental of meeting rooms; rental of facilities for exhibitions; rental of futon and quilts; rental of pillows; rental of blankets; rental of electric hot plates for household purposes; rental of electric toasters for household purposes; rental of microwave ovens for household purposes; rental of cooking equipment for industrial purposes; rental of kitchen sinks incorporating integrated worktops for commercial use; rental of kitchen sinks for commercial use; rental of non-electric cooking heaters for household purposes; rental of kitchen sinks incorporating integrated worktops for household purposes; rental of kitchen sinks for household purposes; rental of dishes; rental of curtains; rental of furniture; rental of wall hangings; rental of floor coverings; rental of towels for hotels; rental of towels for restaurants; rental of towels. Beauty salons; barbershops; providing bath houses; garden tree planting; garden or flower bed care; fertilizer spreading; weed killing; vermin exterminating [for agriculture, aquaculture, horticulture or forestry]; landscape design; massage and therapeutic shiatsu massage; chiropractic; moxibustion; treatment for dislocated joints, sprain, bone fractures [judo- seifuku]; bodywork therapy; acupuncture; providing medical information; physical examination; dietary and nutritional guidance; animal breeding; veterinary services; beautification for animals; nursing care; rental of potted plants; farming equipment rental; rental of medical apparatus and instruments; rental of fishing equipment and instruments; rental of apparatus and instruments for use in beauty salons or barbers' shops; rental of lawnmowers.

21.

PROPHYLACTIC/THERAPEUTIC AGENT FOR PREGNANCY-INDUCED HYPERTENSION

      
Application Number JP2024017419
Publication Number 2024/237199
Status In Force
Filing Date 2024-05-10
Publication Date 2024-11-21
Owner
  • NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (Japan)
  • MEDICAL CORPORATION SANEIKAI (Japan)
  • NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Matsumoto Kunio
  • Imamura Ryu
  • Kato Yukio
  • Masuo Yusuke
  • Mizutani Shigehiko
  • Kajiyama Hiroaki
  • Yoshihara Masato

Abstract

The present invention addresses the problem of providing a prophylactic and/or therapeutic agent for hypertensive disorders of pregnancy, which has a physical property or a molecular weight that inhibits the passage through the placental barrier, has a pharmacological activity that mimics the original physiological function of the placenta and therefore has fewer adverse side effects, is safe for a mother body and a fetus, is stable for a long period, and can exert the efficacy thereof in vivo for a long period. The present invention is a prophylactic/therapeutic agent for pregnancy-induced hypertension, which contains aminopeptidase A (APA) as an active ingredient, the prophylactic/therapeutic agent being characterized in that the APA is bound to an immunoglobulin Fc region through a peptide linker.

IPC Classes  ?

  • A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
  • A61P 9/12 - Antihypertensives
  • C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
  • C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 19/00 - Hybrid peptides
  • C12N 9/50 - Proteinases
  • C12N 15/13 - Immunoglobulins
  • C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
  • C12N 15/62 - DNA sequences coding for fusion proteins

22.

SCREENING METHOD

      
Application Number JP2024017354
Publication Number 2024/232426
Status In Force
Filing Date 2024-05-10
Publication Date 2024-11-14
Owner
  • NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Yoshihara,masato
  • Kajiyama,hiroaki
  • Enomoto,atsushi

Abstract

It has been difficult to quantify the degree of epithelial-mesenchymal transition of peritoneal mesothelial cells from cell morphology, and no biomarker specific for epithelial-mesenchymal transition of mesothelial cells has been known. Provided is a method for screening a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, the method including the following steps: (a) a step for treating mesothelial cells with a candidate substance; (b) a step for determining the expression or activity level of LRRN4 (leucine rich repeat neuronal 4) in the mesothelial cells; and (c) a step for, when the expression or activity level of LRRN4 is increased as compared with the level before the treatment, then selecting the candidate substance as a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells.

IPC Classes  ?

  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
  • A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
  • A61P 15/00 - Drugs for genital or sexual disordersContraceptives
  • A61P 35/04 - Antineoplastic agents specific for metastasis
  • G01N 33/15 - Medicinal preparations
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

23.

SKIN PERMEATION PROMOTER FOR HYALURONIC ACID, SKIN PERMEATION PROMOTION METHOD FOR HYALURONIC ACID, SKIN PERMEATION INHIBITOR FOR HYALURONIC ACID, AND SKIN PERMEATION INHIBITION METHOD FOR HYALURONIC ACID

      
Application Number JP2024015222
Publication Number 2024/219410
Status In Force
Filing Date 2024-04-17
Publication Date 2024-10-24
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kodama Takashi
  • Tse Maying Tsemay

Abstract

The present invention addresses the problem of controlling the skin's permeability of hyaluronic acid. Specifically, a purpose of the present invention is to provide a technology for promoting or inhibiting the skin's permeability of a specific hyaluronic acid, in a skin topical composition. Another purpose of the present invention is to provide a skin topical composition that, by controlling the skin's permeability of hyaluronic acid, provides excellent feelings of use such as feeling of moistness, feeling of plumpness, permeation feeling, skin compatibility, and feeling of wetness. To solve the problem, the present invention is a skin penetration promoter that is for (B) a hyaluronic acid having a weight average molecular weight of at least 1,000,000, a hyaluronic acid derivative, or a salt thereof, and that comprises (A) a hyaluronic acid having a weight average molecular weight of at most 600,000, a hyaluronic acid derivative, or a salt thereof. The present invention is also a skin penetration inhibitor that is for (D) a hyaluronic acid having a weight average molecular weight of at most 100,000, a hyaluronic acid derivative, or a salt thereof, and that comprises (C) a hyaluronic acid having a weight average molecular weight of at least 600,000, a hyaluronic acid derivative, or a salt thereof.

IPC Classes  ?

24.

OPHTHALMIC COMPOSITION

      
Application Number JP2024013119
Publication Number 2024/204749
Status In Force
Filing Date 2024-03-29
Publication Date 2024-10-03
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Hayashi Saeko
  • Kitazawa Shota
  • Takemoto Kohei
  • Morikawa Takuto

Abstract

The present invention relates to an ophthalmic composition containing a Janus kinase inhibitor, the ophthalmic composition being accommodated in a container sterilized by a means other than an electron beam.

IPC Classes  ?

  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 27/02 - Ophthalmic agents

25.

AQUEOUS COMPOSITION

      
Application Number JP2024011038
Publication Number 2024/203727
Status In Force
Filing Date 2024-03-21
Publication Date 2024-10-03
Owner
  • TSUBOTA LABORATORY, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Nishimoto Akinori
  • Oritani Rika

Abstract

The present invention relates to an aqueous composition containing: (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof; and (B) a chelating agent.

IPC Classes  ?

  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 9/08 - Solutions
  • A61K 47/04 - Non-metalsCompounds thereof
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61P 3/00 - Drugs for disorders of the metabolism
  • A61P 27/02 - Ophthalmic agents
  • A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

26.

MESENCHYMAL STEM CELL GROWTH PROMOTER, MEDIUM FOR MESENCHYMAL STEM CELLS, MESENCHYMAL STEM CELLS AND CULTURE SUPERNATANT

      
Application Number JP2024011362
Publication Number 2024/195863
Status In Force
Filing Date 2024-03-22
Publication Date 2024-09-26
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ishikawa Noriyasu
  • Abe Masamichi
  • Okamoto Daiki

Abstract

The purpose of the present invention is to provide a medium for culture excellent in growth of mesenchymal stem cells. The present invention is a mesenchymal stem cell growth promoter containing 16:0 lysophosphatidic acid, a derivative of 16:0 lysophosphatidic acid, and/or a salt thereof. The mesenchymal stem cell growth promoter of the present invention preferably also contains 18:1 lysophosphatidic acid, a derivative of 18:1 lysophosphatidic acid, and/or a salt thereof. The present invention also includes a medium for mesenchymal stem cells that contains16:0 lysophosphatidic acid, a derivative of 16:0 lysophosphatidic acid, and/or a salt thereof.

IPC Classes  ?

  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

27.

LIQUID AGENT CONTAINER

      
Application Number JP2024007706
Publication Number 2024/181552
Status In Force
Filing Date 2024-03-01
Publication Date 2024-09-06
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Kato, Hiroyuki

Abstract

The present disclosure addresses the problem of providing a liquid agent container that readily assumes a structure corresponding to the viscosity of a liquid agent. A liquid agent container (1) comprising: a hollow cylindrical nozzle (2) that has a discharge port (20) at the distal end thereof; a ball valve (3) that is held within the nozzle (2); and a container body (4) that is connected to the nozzle (2) and is flexible, a liquid agent (L1) being accommodated in the container body (4). The nozzle (2) has an abutment surface (21) that abuts the ball valve (3) across the circumferential direction, and a holding part (22) that holds the ball valve (3) in a state of abutting the abutment surface (21). The abutment surface (21) is provided with a groove (5) that links the discharge port (20) and a space inside the nozzle (2), the space being closer to the container body (4) than the abutment surface (21).

IPC Classes  ?

  • B65D 83/00 - Containers or packages with special means for dispensing contents
  • B65D 35/46 - Closures with valves
  • B65D 47/20 - Closures with discharging devices other than pumps comprising hand-operated members for controlling discharge

28.

TEARSHIELD TECHNOLOGY

      
Application Number 234693800
Status Pending
Filing Date 2024-08-30
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Absorbent cotton; adhesive plasters; adhesive tapes for medical purposes; bandages for dressings; beverages for babies; breast-nursing pads; collyrium; cotton swabs for medical use; diaper covers; disinfectants for contact lenses; ear bandages; empty capsules for pharmaceuticals; eye drops; eyepatches for medical purposes; fly catching paper; food for babies; gauze for dressings; lacteal flour for babies; liquid bandages; medicated eye-washes; menstruation bandages; menstruation tampons; mothproofing paper; reagent paper for medical purposes; sanitary napkins; sanitary panties; solutions for contact lenses (2) Pharmaceutical preparations; Cleaning stock solution for contact lenses that increases moisture; Rinsing, cleaning, preserving solution for contact lenses; Eyewashes that are used while wearing contact lenses; Eye drops for use while wearing contact lenses; Contact lens solutions for cleaning, disinfecting and preserving purposes; Oiled paper for medical purposes; Dental materials; Diapers; Dietary supplements for humans; Dietetic beverages adapted for medical purposes; Dietetic food adapted for medical purposes; Dietary supplements for animals; Semen for artificial insemination;

29.

OIL-IN-WATER EXTERNAL COMPOSITION

      
Application Number JP2024002991
Publication Number 2024/162373
Status In Force
Filing Date 2024-01-31
Publication Date 2024-08-08
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Isomura,ami

Abstract

Provided is an oil-in-water external composition having excellent suppression of unpleasant odor. An oil-in-water external composition comprising (A) 5% by mass or more non-polar oil, (B) a polar oil and (C) 8% by mass or more ultraviolet scattering agent.

IPC Classes  ?

  • A61K 8/37 - Esters of carboxylic acids
  • A61K 8/06 - Emulsions
  • A61K 8/31 - Hydrocarbons
  • A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

30.

COMPOSITION FOR ALLEVIATING FATIGUE OR PROMOTING RECOVERY FROM FATIGUE

      
Application Number JP2024001431
Publication Number 2024/154817
Status In Force
Filing Date 2024-01-19
Publication Date 2024-07-25
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Yamada,kotaro
  • Nakagawasai,osamu
  • Tan-No,koichi

Abstract

The purpose of the present invention is to provide a composition that contains a component that can be used in the beverage/food field and is effective on fatigue. The present invention provides a composition for alleviating fatigue or promoting the recovery from fatigue, a composition for improving exercise capabilities, a composition for enhancing physical strength, a composition for reducing blood lactic acid level, or a composition for inhibiting lactic acidosis, which contains a globin protein decomposition product. The present invention also provides a composition for alleviating fatigue or promoting the recovery from fatigue, a composition for improving exercise capabilities, a composition for enhancing physical strength, a composition for reducing blood lactic acid level, or a composition for inhibiting lactic acidosis, which contains a tetrapeptide represented by the formula: Val-Val-Tyr-Pro.

IPC Classes  ?

31.

EMULSIFIED TOPICAL COMPOSITION AND METHOD FOR PRODUCING SAME

      
Application Number JP2023043131
Publication Number 2024/122465
Status In Force
Filing Date 2023-12-01
Publication Date 2024-06-13
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Oka,masato
  • Inaoka,yumiko

Abstract

Provided is a novel composition having excellent ultraviolet ray absorption capability In the present invention, the following is prepared: an emulsified topical composition containing (C) diethylamino hydroxybenzoyl hexyl benzoate, and (A) porous silica including an ultraviolet absorber, where the average particle diameter of the porous silica is 1.4 to 40 μm, and the ultraviolet absorber included in the (A) component is solid at 25°C; or an emulsified topical composition containing (A2) porous silica including an ultraviolet absorber and (B) a non-ionic surfactant, where the average particle diameter of the porous silica is 1.4 to 40 μm, and the porous silica includes an ultraviolet absorber that is solid at 25°C.

IPC Classes  ?

  • A61K 8/06 - Emulsions
  • A61K 8/25 - SiliconCompounds thereof
  • A61K 8/41 - Amines
  • A61K 8/46 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
  • A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations

32.

ROHTO

      
Application Number 236496100
Status Pending
Filing Date 2024-06-10
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ?
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

(1) Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; laundry starch; seaweed gelatine for laundry use [funori]; adhesives for affixing false eyelashes; breath freshening preparations; deodorants for animals; paint stripping preparations; shoe cream; shoe black [shoe polish]; polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumes and flavourings for beverages [essential oils]; perfumes and food flavourings [essential oils]; incense; abrasive paper [sandpaper]; abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes. (2) Pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination; stem cells for medical, pharmaceutical or veterinary use; stem cells for regenerative medicine, medicine or veterinary use; stem cells (only for medical and veterinary use); diagnostic reagents for clinical or medical laboratory use; diagnostic media for bacteriological cultures; microorganism culture media for medical use; cell culture media for medical or veterinary use; serums; serotherapeutic medicines; fumigants [only for agricultural purposes]; fungicides [only for agricultural purposes]; rodenticides [only for agricultural purposes]; insecticides [only for agricultural purposes]; herbicides [weedkillers]; insect-repellents [only for agricultural purposes]; antiseptics [only for agricultural purposes].

33.

ROHTO

      
Serial Number 79410960
Status Pending
Filing Date 2024-06-10
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ?
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; laundry starch; seaweed gelatine for laundry use (funori); adhesives for affixing false eyelashes; breath freshening preparations; deodorants for animals; paint stripping preparations; shoe cream; shoe black (shoe polish); polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumes and flavourings for beverages (essential oils); perfumes and food flavourings (essential oils); incense; abrasive paper (sandpaper); abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes Pharmaceutical preparations; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for human beings; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements for animals; semen for artificial insemination; stem cells for medical, pharmaceutical or veterinary use; stem cells for regenerative medicine, medicine or veterinary use; stem cells (only for medical and veterinary use); diagnostic reagents for clinical or medical laboratory use; diagnostic media for bacteriological cultures; microorganism culture media for medical use; cell culture media for medical or veterinary use; serums; serotherapeutic medicines; fumigants (only for agricultural purposes); fungicides (only for agricultural purposes); rodenticides (only for agricultural purposes); insecticides (only for agricultural purposes); herbicides (weedkillers); insect-repellents (only for agricultural purposes); antiseptics (only for agricultural purposes)

34.

METHOD FOR PRODUCING GEL-LIKE WOUND HEALING AGENT, GEL-LIKE WOUND HEALING AGENT, AND AUTOLOGOUS PLATELET-RICH PLASMA GEL PREPARATION KIT FOR WOUND HEALING

      
Application Number JP2023042289
Publication Number 2024/117059
Status In Force
Filing Date 2023-11-27
Publication Date 2024-06-06
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shoju Shintaro
  • Kawai Mami
  • Mitsuguchi Yoko

Abstract

The purpose of the present invention is to provide a treatment method and therapeutic agent by which a sufficient effect can be obtained even with regard to a wound or the like for which an improvement trend is not observed with existing treatment methods. The present invention pertains to a method for producing a gel-like wound healing agent, the method comprising a feature of mixing an effective amount of a platelet-rich plasma (A), 150-300 mg/mL of an ascorbic acid solution (B), 1.0-3.0 wt% of a calcium chloride solution (C), and thrombin (D), a mixing ratio of the platelet-rich plasma (A) and the ascorbic acid solution (B) being 1.0-3.0 mL of the ascorbic acid solution (B) per 8.0 mL of the platelet-rich plasma (A), a mixing ratio of the platelet-rich plasma (A) and the calcium chloride solution (C) being 1.0-3.0 mL of the calcium chloride solution (C) per 8.0 mL of the platelet-rich plasma (A), and the amount of thrombin (D) being 500-2000 U per 8.0 mL of the platelet-rich plasma (A).

IPC Classes  ?

  • A61K 35/16 - Blood plasmaBlood serum
  • A61K 9/06 - OintmentsBases therefor
  • A61K 9/70 - Web, sheet or filament bases
  • A61K 47/02 - Inorganic compounds
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
  • A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
  • A61K 35/19 - PlateletsMegacaryocytes

35.

UTERINE TREATMENT COMPOSITION, UTERINE ENVIRONMENT-IMPROVING AGENT, IMPLANTATION AID, EMBRYO TRANSPLANTATION LIQUID, SPERM TRANSPLANTATION LIQUID, AND IMPLANTATION RATE-IMPROVING AGENT

      
Application Number JP2023039207
Publication Number 2024/095996
Status In Force
Filing Date 2023-10-31
Publication Date 2024-05-10
Owner
  • HIROSHIMA UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimada Masayuki
  • Umehara Takashi
  • Ishikawa Noriyasu
  • Takijiri Takashi

Abstract

The purpose of the present invention is to provide an excellent infertility treatment with which it is possible to increase the implantation rate of an embryo (fertilized egg) by improving the uterine environment. The present invention is a uterine treatment composition containing a mesenchymal stem cell culture supernatant, and is used as a uterine environment-improving agent, an implantation aid, an embryo transplant liquid, a sperm transplantation liquid, or an implantation rate-improving agent. The mesenchymal stem cells are preferably derived from adipose tissue, umbilical cord tissue, or bone marrow tissue.

IPC Classes  ?

  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
  • A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
  • A61P 15/00 - Drugs for genital or sexual disordersContraceptives
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

36.

BIOMARKER FOR USE IN PREDICTION OF OCCURRENCE OF ACNE VULGARIS, PREDICTION OF SEVERITY AND DETERMINATION OF SEVERITY

      
Application Number JP2023039756
Publication Number 2024/096129
Status In Force
Filing Date 2023-11-02
Publication Date 2024-05-10
Owner
  • OSAKA UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Matsuoka Yumi
  • Fujimoto Manabu
  • Sugihira Takashi

Abstract

Disclosed is a biomarker for use in the prediction of the occurrence and the severity of acne vulgaris, and in the determination of the severity of acne vulgaris.

IPC Classes  ?

  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
  • C12N 1/20 - BacteriaCulture media therefor
  • C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

37.

SPERM TREATMENT COMPOSITION, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILITY MAINTAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILITY MAINTAINING METHOD

      
Application Number JP2023039262
Publication Number 2024/096009
Status In Force
Filing Date 2023-10-31
Publication Date 2024-05-10
Owner
  • HIROSHIMA UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimada Masayuki
  • Umehara Takashi
  • Ishikawa Noriyasu
  • Takijiri Takashi

Abstract

The purpose of the present invention is to provide sperm having high motility. The present invention is a sperm treatment composition that contains an exosome. A sperm treatment composition according to the present invention is used as a sperm preparation solution, a sperm diluent, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a sperm motility improving solution, or a sperm fertility maintaining solution.

IPC Classes  ?

  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
  • C12N 5/076 - Sperm cellsSpermatogonia

38.

BURDOCK SEED OIL-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME

      
Application Number JP2023036324
Publication Number 2024/075806
Status In Force
Filing Date 2023-10-05
Publication Date 2024-04-11
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Imai,momoko
  • Shimizu,takashi

Abstract

The purpose of the present invention is to produce and provide a burdock seed oil-containing composition that is excellent in stability. The present invention relates to a composition containing (A) burdock seed oil and (B) triethyl citrate and containing 1 to 7.5 mass% of arctigenin derived from the component (A), and a method for producing the same.

IPC Classes  ?

  • A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
  • A61K 31/365 - Lactones
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

39.

GLAUCOMA DETERMINATION SYSTEM AND GLAUCOMA DETERMINATION METHOD

      
Application Number JP2023030029
Publication Number 2024/048351
Status In Force
Filing Date 2023-08-21
Publication Date 2024-03-07
Owner
  • TOHOKU UNIVERSITY (Japan)
  • CASIO COMPUTER CO., LTD. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Nakazawa,toru
  • Tomida,takahiro
  • Otsuka,toshihiko
  • Arita,harumasa

Abstract

Provided is a system for determining the possibility of glaucoma without a large-scale measurement of a myoelectric potential of the heart. This glaucoma determination system (1) comprises a processing unit (112) which acquires index data pertaining to the blood flow of a subject, determines, on the basis of the acquired index data, the possibility of glaucoma pertaining to an eyeball of the subject, and outputs information pertaining to the determined possibility of glaucoma.

IPC Classes  ?

  • A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
  • A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
  • A61B 5/026 - Measuring blood flow
  • A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes

40.

THERAPEUTIC AGENT FOR RENAL DISEASE AND RENAL FUNCTION-IMPROVING AGENT

      
Application Number JP2023030142
Publication Number 2024/043232
Status In Force
Filing Date 2023-08-22
Publication Date 2024-02-29
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ota Shigeyuki
  • Kurata Hayato
  • Koike Tetsuo
  • Nomi Kimihito
  • Yamada Kotaro

Abstract

The purpose of the present invention is to provide a novel therapeutic agent for renal disease. The present invention is a therapeutic agent for renal disease containing a mesenchymal stem cell culture supernatant. The mesenchymal stem cell culture supernatant is preferably a culture supernatant obtained from the cultivation of mesenchymal stem cells derived from adipose tissue, umbilical tissue, or bone marrow tissue. In addition, the mesenchymal stem cell culture supernatant is preferably obtained from the cultivation of mesenchymal stem cells in a culture medium containing at least one substance selected from the group consisting of EGF, bFGF, albumin, transferrin, and insulin.

IPC Classes  ?

  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
  • A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
  • A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

41.

COMPOSITION AND FUNCTIONAL FOOD FOR PREVENTING MYOPIA

      
Application Number 18483161
Status Pending
Filing Date 2023-10-09
First Publication Date 2024-02-01
Owner
  • TSUBOTA LABORATORY, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Tsubota, Kazuo
  • Kurihara, Toshihide

Abstract

The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

IPC Classes  ?

  • A61K 36/16 - Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
  • A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/05 - Phenols
  • A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid

42.

COMPOSITION FOR IMPROVING OCULAR BLOOD FLOW

      
Application Number JP2023026874
Publication Number 2024/019171
Status In Force
Filing Date 2023-07-21
Publication Date 2024-01-25
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Nakazawa,toru
  • Sato,kota
  • Shidomi,miwako
  • Ueda,hisae
  • Tsukamoto,kosei

Abstract

The purpose of the present invention is to provide a composition that improves conditions related to ocular blood flow by evaluating effects on ocular blood flow. Provided is a composition for improving and/or maintaining ocular blood flow, said composition containing Zingiber officinale and/or an extract thereof. Also provided are a composition for maintaining the health of vascular tissues in the ocular region, a composition for anti-aging of the ocular region, a composition for improving and/or maintaining the health of the ocular region, visual field narrowing, visual field defects or the appearance or expansion of a dark spot, and a composition for treating and/or preventing ocular circulation disorders, each composition containing the aforesaid ingredient.

IPC Classes  ?

  • A61K 36/906 - Zingiberaceae (Ginger family)
  • A23L 2/52 - Adding ingredients
  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • A61P 27/02 - Ophthalmic agents
  • A61P 27/06 - Antiglaucoma agents or miotics

43.

GINGER-CONTAINING COMPOSITION

      
Application Number JP2023027000
Publication Number 2024/019179
Status In Force
Filing Date 2023-07-24
Publication Date 2024-01-25
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Morikawa,saki
  • Furukawa,yusuke

Abstract

Provided is a composition comprising ginger and lutein and/or crocetin, wherein decomposition over time of the components contained in the composition is suppressed. Also provided is a method for suppressing decomposition of the composition components and a method for producing the composition. The composition comprises: (A) one or more selected from the group consisting of Zingiber officinale var. Rubra and extracts thereof; and (B) one or more selected from the group consisting of lutein and crocetin.

IPC Classes  ?

  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof

44.

SYSTEM FOR DETERMINING DEPRESSION RISK USING FUNDUS IMAGE, MACHINE LEARNING MODEL GENERATION DEVICE, DEPRESSION RISK DETERMINATION DEVICE, AND DEPRESSION RISK DETERMINATION METHOD

      
Application Number JP2023020636
Publication Number 2024/014175
Status In Force
Filing Date 2023-06-02
Publication Date 2024-01-18
Owner
  • SAI CORPORATION (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
  • OSAKA UNIVERSITY (Japan)
Inventor
  • Fukuma Yasufumi
  • Mao Zaixing
  • Kurose Takahiro
  • Sone Kohei
  • Nishida Kohji
  • Kawasaki Ryo
  • Maruyama Kazuichi
  • Matsushita Kenji
  • Hashida Noriyasu

Abstract

Provided is a depression risk determining system with which it is possible to determine the risk of depression from a fundus image. The system for determining depression risk according to the present invention comprises: a machine learning model generation device that generates a trained model for determining the risk of depression; and a depression risk determination device that determines the risk of depression by using the trained model generated by the machine learning model generation device. The machine learning model generation device includes a data acquisition unit that acquires at least inquiry data for training and a fundus image for training, and a machine learning model generation unit that generates a trained model. The depression risk determination device includes a determination data acquisition unit that acquires a fundus image used for determination, a depression risk determination unit that inputs at least the fundus image used for determination to the trained model to thereby output a prediction score indicating depression risk, and a determination result output unit that outputs the determination results of depression risk on the basis of the prediction score.

IPC Classes  ?

  • G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

45.

OPHTHALMIC COMPOSITION

      
Application Number JP2023024965
Publication Number 2024/010039
Status In Force
Filing Date 2023-07-05
Publication Date 2024-01-11
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ogawa Yoko
  • Kitazawa Shota

Abstract

The present invention relates to an ophthalmic composition containing tramadol or a salt thereof. This ophthalmic composition has a pH of 4.0 to 6.8 and is stored in a container in which a portion of or all of the part thereof contacting this ophthalmic composition is formed from plastic.

IPC Classes  ?

46.

OPHTHALMIC COMPOSITION

      
Application Number JP2023024968
Publication Number 2024/010040
Status In Force
Filing Date 2023-07-05
Publication Date 2024-01-11
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ogawa Yoko
  • Kitazawa Shota

Abstract

The present invention relates to an ophthalmic composition containing tramadol or a salt thereof, and a biguanide-based preservative.

IPC Classes  ?

  • A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
  • A61K 9/08 - Solutions
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61P 27/02 - Ophthalmic agents

47.

PAIN SUPPRESSANT

      
Application Number JP2023024981
Publication Number 2024/010045
Status In Force
Filing Date 2023-07-05
Publication Date 2024-01-11
Owner
  • KANAZAWA MEDICAL UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Nagaoka Shogo
  • Masuoka Takayoshi

Abstract

The present invention relates to a pain suppressant for the trigeminal nerve, the pain suppressant containing tramadol or a salt thereof.

IPC Classes  ?

  • A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
  • A61K 9/08 - Solutions
  • A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
  • A61P 27/02 - Ophthalmic agents

48.

OPHTHALMIC COMPOSITION

      
Application Number JP2023024976
Publication Number 2024/010043
Status In Force
Filing Date 2023-07-05
Publication Date 2024-01-11
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Ogawa Yoko

Abstract

The present invention relates to an ophthalmic composition which contains tramadol or a salt thereof and does not substantially contain a preservative agent.

IPC Classes  ?

  • A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
  • A61K 9/08 - Solutions
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61P 27/02 - Ophthalmic agents

49.

OPHTHALMIC COMPOSITION

      
Application Number JP2023024978
Publication Number 2024/010044
Status In Force
Filing Date 2023-07-05
Publication Date 2024-01-11
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ogawa Yoko
  • Kitazawa Shota

Abstract

The present invention relates to an ophthalmic composition containing tramadol or a salt thereof, wherein the ophthalmic composition is accommodated in a container of which part or all of a portion coming into contact with the ophthalmic composition is formed from a plastic, and the container is subjected to a sterilization treatment by a means other than an electron beam.

IPC Classes  ?

  • A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
  • A61K 9/08 - Solutions
  • A61K 47/04 - Non-metalsCompounds thereof
  • A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
  • A61P 27/02 - Ophthalmic agents

50.

BIOMARKER OF SKIN AGING, METHOD FOR DETERMINING SKIN AGING, AND METHOD FOR SCREENING SKIN AGING IMPROVEMENT SUBSTANCE

      
Application Number JP2023022650
Publication Number 2023/243732
Status In Force
Filing Date 2023-06-19
Publication Date 2023-12-21
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Florence Florence
  • Haga Masatoshi
  • Sato Yasunari

Abstract

The objective of the present invention is to provide a biomarker for use in determination of skin aging, comprising a protein or a fragment thereof. Alternatively, the objective of the present invention is to provide a method for determining skin aging in a subject, characterized in measuring a protein or a fragment thereof in a blood sample of the subject. Yet alternatively, the objective of the present invention is to provide a method for screening a skin aging improvement substance, characterized in studying an expression level of or a concentration change in a protein or a fragment thereof in a blood sample of a subject before and after intake of a test substance by the subject. The present invention is a biomarker for use in determination of skin aging, comprising a protein selected from the group consisting of: osteomodulin (OMD); chondroadherin (CHAD); collagen type XI alpha 2 chain (COL11A2); leucine-rich repeat-containing protein 15 (LRRC15); glycoprotein hormones alpha chain/choriogonadotropin subunit beta 3/choriogonadotropin subunit beta 7 (CGA/CGB3/CGB7); lutropin subunit beta (LHB); glycoprotein hormones alpha chain/lutropin subunit beta (CGA/LHB); and glycoprotein hormones alpha chain/follitropin subunit beta (CGA/FSHB), or a fragment thereof.

IPC Classes  ?

  • C12N 15/12 - Genes encoding animal proteins
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

51.

COMPOSITION FOR AMELIORATING UNPLEASANT STATE CAUSED BY MENSTRUATION

      
Application Number 18023119
Status Pending
Filing Date 2021-08-25
First Publication Date 2023-10-19
Owner
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
  • LINK GENOMICS, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Katabuchi, Hidetaka
  • Honda, Ritsuo
  • Niwa, Shinichiro
  • Kitadai, Eri
  • Mizunuma, Hidemi
  • Arita, Harumasa

Abstract

The object of the present invention is to provide: a composition for ameliorating an unpleasant state caused by menstruation, which is effective against discomfort occurring in women in the period from the first menstruation to menopause, particularly strong discomfort occurring in young women, has been sufficiently experienced as a foodstuff and has an anti-EMT activity; and a functional food containing the composition. A composition for ameliorating an unpleasant state caused by menstruation is prepared, which comprises at least one component selected from the group consisting of black rice, cherry blossom, and extracts thereof.

IPC Classes  ?

  • A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
  • A61P 15/00 - Drugs for genital or sexual disordersContraceptives
  • A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

52.

AQUEOUS COMPOSITION

      
Application Number JP2023011739
Publication Number 2023/182480
Status In Force
Filing Date 2023-03-24
Publication Date 2023-09-28
Owner
  • TSUBOTA LABORATORY, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Oritani Rika
  • Kitani Chise
  • Nishimoto Akinori

Abstract

A first invention pertains to an aqueous composition that contains (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and that is housed in a container in which all or a portion thereof in contact with the aqueous composition is formed of a resin containing a polyolefin. A second invention pertains to an aqueous composition containing (A) 4-phenylbutyric acid or an ester thereof, or a pharmacologically acceptable salt thereof, and (B) a chelating agent.

IPC Classes  ?

  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 47/02 - Inorganic compounds
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61P 27/02 - Ophthalmic agents

53.

Aqueous Composition

      
Application Number 18018105
Status Pending
Filing Date 2021-07-30
First Publication Date 2023-09-14
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor
  • Kubo, Ozora
  • Hayashi, Saeko
  • Kita, Akiko

Abstract

The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of citric acid, phosphoric acid, and a salt thereof (B).

IPC Classes  ?

  • A61K 47/02 - Inorganic compounds
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof

54.

Aqueous Composition

      
Application Number 18018108
Status Pending
Filing Date 2021-07-30
First Publication Date 2023-09-14
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor
  • Kubo, Ozora
  • Hayashi, Saeko
  • Kita, Akiko

Abstract

The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof (A) and at least one selected from the group consisting of edetic acid, creatinine, and a salt thereof (B).

IPC Classes  ?

  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/08 - Solutions
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

55.

PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DIABETES

      
Application Number 18016978
Status Pending
Filing Date 2022-02-09
First Publication Date 2023-09-07
Owner
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
  • OSAKA UNIVERSITY (Japan)
Inventor
  • Kita, Shunbun
  • Horitani, Emi
  • Maeda, Norikazu
  • Shimomura, Iichiro
  • Nishida, Hiroyuki

Abstract

The present invention aims to provide a prophylactic and/or therapeutic agent for diabetes that is highly effective on diabetes developed as a side effect from immune checkpoint inhibitors and has a certain effect on many patients. The present invention is a therapeutic agent for diabetes comprising mesenchymal stem cells. The prophylactic and/or therapeutic agents for diabetes of the present invention are suitably used particularly for diabetes caused by immune checkpoint inhibitors and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.

IPC Classes  ?

  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

56.

COMPOSITION FOR AMELIORATING UNPLEASANT STATE CAUSED BY MENSTRUATION

      
Application Number JP2023007574
Publication Number 2023/167236
Status In Force
Filing Date 2023-03-01
Publication Date 2023-09-07
Owner
  • LINK GENOMICS, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Niwa,shinichiro
  • Kitadai,eri
  • Mizunuma,hidemi
  • Nishimori,tomoharu
  • Arita,harumasa
  • Kubo,ozora
  • Wu,yihao

Abstract

The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopause, in particular, a strongly unpleasant feeling felt by young females, the composition having anti-EMT activity and being commonly consumed as foodstuff; and a functional food containing said composition. The present invention prepares a composition for ameliorating an unpleasant state related to menstruation, containing plant-based polyphenol.

IPC Classes  ?

  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
  • A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
  • A61P 5/24 - Drugs for disorders of the endocrine system of the sex hormones
  • A61P 7/06 - Antianaemics
  • A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
  • A61P 25/06 - Antimigraine agents
  • A61P 25/24 - Antidepressants

57.

METHOD FOR PREPARING CELLS FOR TREATING DISEASES, METHOD FOR PROMOTING MIGRATION ABILITY OF CELLS, METHOD FOR PROMOTING PROLIFERATION ABILITY OF CELLS, AND CELLS OBTAINED BY THESE METHODS

      
Application Number JP2023002483
Publication Number 2023/149351
Status In Force
Filing Date 2023-01-26
Publication Date 2023-08-10
Owner
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
  • SONIKURE HOLDINGS LIMITED (China)
Inventor
  • Kurogi Hikari
  • Arya Smriti
  • Choi Ka Ming
  • Lo Hau Yi Paulisally
  • Suen Wai Leung Langston
  • Lau Wai Ki
  • Armstrong Jamison Thomas

Abstract

An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.

IPC Classes  ?

  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

58.

MYOPIA-INDUCED MODEL BY OCULAR INSTILLATION OF DRUG

      
Application Number JP2023001374
Publication Number 2023/145578
Status In Force
Filing Date 2023-01-18
Publication Date 2023-08-03
Owner
  • TSUBOTA LABORATORY, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Tsubota Kazuo
  • Kurihara Toshihide
  • Ikeda Shinichi

Abstract

The present invention provides a method for evaluating the efficacy of a physical or chemical means on the treatment of myopia in vivo, the method comprising: a treatment step for applying the physical or chemical means to a myopia-induced model animal in which a signaling system associated with endoplasmic reticulum stress is activated; a measurement step for measuring a myopia-associated biomarker in the animal to which the physical or chemical treatment has been applied, after a lapse of a predetermined period of time after the treatment step; and a determination step for determining that the physical or chemical means is effective on the treatment of myopia in vivo when the following determination criterion is satisfied. The determination criterion: the amount of the change in the myopia-associated biomarker from a value before the activation of the signaling system associated with endoplasmic reticulum stress to the measured value is smaller than that in a myopia-induced model animal that has not been influenced by the physical or chemical means (i.e., a control).

IPC Classes  ?

  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
  • G01N 33/15 - Medicinal preparations

59.

SUNPLAY

      
Application Number 1742261
Status Registered
Filing Date 2023-06-09
Registration Date 2023-06-09
Owner ROHTO Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations

Goods & Services

Antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; stain removing benzine; fabric softeners for laundry use; laundry bleach; adhesives for affixing false hair; adhesives for affixing false eyelashes; laundry starch; seaweed gelatine for laundry use [funori]; paint stripping preparations; shoe cream; shoe black [shoe polish]; polishing preparations; soaps and detergents; dentifrices; cosmetics; perfumery, fragrances and incenses (other than perfumes used as cosmetics or toiletries); abrasive paper [sandpaper]; abrasive cloth; abrasive sand; artificial pumice stone; polishing paper; false nails; false eyelashes.

60.

COMPOSITION FOR SPERM TREATMENT, SPERM MOTILITY IMPROVING AGENT, SPERM FERTILIZING CAPABILITY RETAINING AGENT, SPERM MOTILITY IMPROVING METHOD, AND SPERM FERTILIZING CAPABILITY RETAINING METHOD

      
Application Number JP2023001660
Publication Number 2023/140347
Status In Force
Filing Date 2023-01-20
Publication Date 2023-07-27
Owner
  • HIROSHIMA UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimada Masayuki
  • Umehara Takashi
  • Ishikawa Noriyasu
  • Takijiri Takashi

Abstract

The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for sperm treatment that contains medium for mesenchymal stem cells. This composition for sperm treatment is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for sperm treatment is preferably a serum-free medium.

IPC Classes  ?

  • C12N 5/076 - Sperm cellsSpermatogonia
  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
  • C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor

61.

COMPOSITION FOR SPERMATOZOA TREATMENT, SPERMATOZOA MOTILITY ENHANCEMENT AGENT, SPERMATOZOA FERTILITY RETENTION AGENT, SPERMATOZOA MOTILITY ENHANCEMENT METHOD, AND SPERMATOZOA FERTILITY RETENTION METHOD

      
Application Number JP2023001663
Publication Number 2023/140348
Status In Force
Filing Date 2023-01-20
Publication Date 2023-07-27
Owner
  • HIROSHIMA UNIVERSITY (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Shimada Masayuki
  • Umehara Takashi
  • Ishikawa Noriyasu
  • Takijiri Takashi

Abstract

The purpose of the present invention is to provide spermatozoa having high motility. The present invention is a composition for spermatozoa treatment that includes a mesenchymal stem cell culture supernatant. The composition for spermatozoa treatment of the present invention is used as a spermatozoa adjustment liquid, a spermatozoa dilution liquid, a spermatozoa preservation liquid, an artificial insemination solution, an in vitro fertilization solution, a solution for spermatozoa motility enhancement, or a solution for spermatozoa fertility retention. Furthermore, mesenchymal stem cells in the mesenchymal stem cell culture supernatant included in the composition for spermatozoa treatment are preferably derived from adipose tissue, derived from umbilical cord tissue, or derived from bone marrow tissue.

IPC Classes  ?

  • C12N 5/076 - Sperm cellsSpermatogonia
  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
  • C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor

62.

PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION WHICH CONTAINS BENZOYL PEROXIDE

      
Application Number JP2022044017
Publication Number 2023/112664
Status In Force
Filing Date 2022-11-29
Publication Date 2023-06-22
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Marukawa Junko
  • Hayashi Ayako

Abstract

A pharmaceutical composition for external application which comprises (A) benzoyl peroxide and (B) at least one component selected from (B1) glycyrrhetinic acid and derivatives and salts thereof and (B2) allantoin does not undergo the decrease in viscosity over time and can be applied and spread smoothly on the skin.

IPC Classes  ?

  • A61K 31/327 - Peroxy compounds, e.g. hydroperoxides, peroxides, peroxy acids
  • A61K 9/06 - OintmentsBases therefor
  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
  • A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

63.

Ophthalmic Composition

      
Application Number 17921065
Status Pending
Filing Date 2021-03-31
First Publication Date 2023-06-08
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor
  • Ando, Tatsuya
  • Mitsuguchi, Yoko
  • Matsumoto, Sachiko
  • Nakata, Atsuko

Abstract

The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.

IPC Classes  ?

  • A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
  • A61K 31/355 - Tocopherols, e.g. vitamin E
  • A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
  • A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
  • A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
  • A61K 47/38 - CelluloseDerivatives thereof
  • A61K 31/4415 - Pyridoxine, i.e.vitamin B6
  • A61K 31/16 - Amides, e.g. hydroxamic acids
  • A61P 27/04 - Artificial tearsIrrigation solutions
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
  • A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin

64.

AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS

      
Application Number 17918390
Status Pending
Filing Date 2021-04-09
First Publication Date 2023-05-25
Owner
  • NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Maruyama, Shoichi
  • Furuhashi, Kazuhiro
  • Tanaka, Akihito
  • Karasawa, Munetoshi
  • Takao, Yukinari

Abstract

The present invention addresses the problem of providing a fundamental therapeutic method for renal diseases including glomerulonephritis such as IgA nephropathy. To solve this problem, the present invention pertains to an agent for increasing CD25-positive regulatory T cells in kidney, said agent comprising mesenchymal stem cells. The regulatory T cell-increasing agent of the present invention exerts a sufficient therapeutic effect even if further containing a cryopreservation liquid at a concentration of less than 5% (v/v).

IPC Classes  ?

  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
  • A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

65.

OILY SOLID COMPOSITION FOR EXTERNAL USE

      
Application Number JP2022043126
Publication Number 2023/090454
Status In Force
Filing Date 2022-11-22
Publication Date 2023-05-25
Owner
  • THE MENTHOLATUM COMPANY (USA)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Kawaguchi,yoshiaki

Abstract

Provided is an oily solid composition for external use with excellent stability. The oily solid composition for external use, containing: (A) an oily component having a melting point of 55°C or higher; (B) a polyhydric alcohol; and (C) an acrylic acid-based water-soluble polymer, is prepared.

IPC Classes  ?

  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
  • A61P 5/44 - GlucocorticosteroidsDrugs increasing or potentiating the activity of glucocorticosteroids

66.

OPHTHALMIC COMPOSITION

      
Application Number JP2021040030
Publication Number 2023/073925
Status In Force
Filing Date 2021-10-29
Publication Date 2023-05-04
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ando Tatsuya
  • Mitsuguchi Yoko
  • Matsumoto Sachiko
  • Nakata Atsuko
  • Kiyobayashi Yuka

Abstract

A first aspect of the present invention relates to an ophthalmic composition for suppressing the dryness of the eyes, the ophthalmic composition containing at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof. A second aspect of the present invention relates to an ophthalmic composition comprising at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof and at least one component selected from the group consisting of an antihistaminic agent, a zinc salt, tetrahydrozoline and salts thereof, hydroxyethyl cellulose and salts thereof and a polyvinyl-based polymeric compound. A third aspect of the present invention relates to an ophthalmic composition comprising at least one component selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 40,000 to 70,000 and salts thereof and menthol.

IPC Classes  ?

  • A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61P 27/02 - Ophthalmic agents

67.

WATER-IN-OIL COMPOSITION FOR EXTERNAL USE CONTAINING ASCORBIC ACID AND/OR SALT THEREOF

      
Application Number JP2022035377
Publication Number 2023/054168
Status In Force
Filing Date 2022-09-22
Publication Date 2023-04-06
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kitaoka,yu
  • Yamamoto,hitomi

Abstract

Provided is a water-in-oil composition for external use that contains ascorbic acid or a salt thereof. This prepared water-in-oil composition for external use contains: (A) at least one selected from the group consisting of ascorbic acid and an ascorbic acid salt; (B) propanediol; (C) an oil component; and (D) a silicone-based surfactant. This water-in-oil composition for external use has good stability.

IPC Classes  ?

  • A61K 8/67 - Vitamins
  • A61K 8/06 - Emulsions
  • A61K 8/34 - Alcohols
  • A61K 8/891 - Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
  • A61K 8/894 - Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
  • A61K 9/107 - Emulsions
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
  • A61P 17/00 - Drugs for dermatological disorders
  • A61P 17/10 - Anti-acne agents
  • A61P 17/18 - Antioxidants, e.g. antiradicals
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
  • A61P 39/06 - Free radical scavengers or antioxidants
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • A61Q 19/00 - Preparations for care of the skin
  • A61Q 19/08 - Anti-ageing preparations

68.

OPHTHALMOLOGICAL COMPOSITION

      
Application Number JP2022036673
Publication Number 2023/054669
Status In Force
Filing Date 2022-09-30
Publication Date 2023-04-06
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Morikawa Takuto
  • Matsumoto Sachiko
  • Matsuki Rie

Abstract

The present disclosure pertains to an ophthalmological composition containing: (A) zinc chloride; and (B) a polyvinyl polymer compound.

IPC Classes  ?

69.

Resin container and resin container connected body

      
Application Number 17770298
Grant Number 12295910
Status In Force
Filing Date 2019-10-21
First Publication Date 2023-03-30
Grant Date 2025-05-13
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor
  • Koshiro, Hiroyuki
  • Ikeda, Naohiro

Abstract

The present invention is a resin container having a multilayer structure including a first layer that comes into contact with liquid content and a second layer that is in contact with the first layer from an outer side of the first layer. The first layer includes a cyclic olefin copolymer and a linear low-density polyethylene resin, and the second layer includes a low-density polyethylene resin.

IPC Classes  ?

  • A61J 1/06 - Ampoules or cartridges
  • A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
  • B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
  • B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins
  • B65D 1/09 - Ampoules

70.

Aqueous Composition

      
Application Number 17788378
Status Pending
Filing Date 2020-12-25
First Publication Date 2023-03-30
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor
  • Nishimoto, Akinori
  • Kita, Akiko
  • Hayashi, Saeko

Abstract

The present invention relates to an aqueous composition comprising delgocitinib or a salt thereof and having a pH of 4.0 to 6.5.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 9/08 - Solutions

71.

METHOD FOR EVALUATING AND/OR SCREENING A CONTROL AGENT FOR TISSUE MORPHOLOGY AND/OR TISSUE FUNCTION

      
Application Number 17793184
Status Pending
Filing Date 2020-10-19
First Publication Date 2023-02-23
Owner
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
  • RIKEN (Japan)
Inventor
  • Kimura, Shun
  • Tsuji, Takashi

Abstract

An object of the present invention is to provide a new method for evaluating and/or screening an excellent healthcare material or pharmaceutical product based on a new concept. The present invention to solve the above object is a method for evaluating and/or screening a control agent for tissue morphology and/or tissue function, the method including: applying a test substance to a tissue or cell capable of expressing a mechanical stress signaling molecule; and evaluating expression, activity, or intracellular localization of the mechanical stress signaling molecule in the tissue or cell.

IPC Classes  ?

  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

72.

CLEANING COMPOSITION AND PRODUCTION METHOD FOR SAME

      
Application Number JP2022030065
Publication Number 2023/017790
Status In Force
Filing Date 2022-08-05
Publication Date 2023-02-16
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Masuda Kenta

Abstract

Provided is a cleaning composition that has excellent usability and makes it possible to suppress reduction in the enzymatic activity of a proteolytic enzyme or a lipolytic enzyme. According to the present invention, a cleaning composition contains (A) a higher fatty acid and/or a salt thereof, (B) a proteolytic enzyme and/or a lipolytic enzyme, (C) a polyalcohol, and (D) water. The (C) content is 25–60 mass% of the entire cleaning composition. The (D) content is 5–30 mass% of the entire cleaning composition. The cleaning composition contains glycerin and/or sorbitol as (C), and the glycerin and/or sorbitol content is 10–60 mass% of the entire cleaning composition.

IPC Classes  ?

73.

KIT FOR PREPARING DISEASE-TREATING AGENT, DISEASE-TREATING AGENT AND METHOD FOR PREPARING DISEASE-TREATING AGENT

      
Application Number 17881413
Status Pending
Filing Date 2022-08-04
First Publication Date 2023-02-02
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Sawa, Yoshiki
  • Miyagawa, Shigeru
  • Kajita, Daisuke
  • Tamada, Kotoe

Abstract

Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.

IPC Classes  ?

  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • A61K 9/06 - OintmentsBases therefor
  • A61K 9/08 - Solutions
  • A61K 38/36 - Blood coagulation or fibrinolysis factors
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 9/12 - AerosolsFoams
  • A61K 9/10 - DispersionsEmulsions
  • A61P 9/00 - Drugs for disorders of the cardiovascular system
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61P 27/02 - Ophthalmic agents
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups

74.

Lacrifast

      
Application Number 018824756
Status Registered
Filing Date 2023-01-20
Registration Date 2023-05-19
Owner ROHTO Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 10 - Medical apparatus and instruments

Goods & Services

Implants for treating eye disorders, namely medical tubes for occlusion lacrimal passage.

75.

Resin container and resin container connected body

      
Application Number 17770302
Grant Number 12186264
Status In Force
Filing Date 2019-10-21
First Publication Date 2022-12-22
Grant Date 2025-01-07
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor
  • Ikeda, Naohiro
  • Kawai, Keita

Abstract

The present invention is a resin container in which an inner wall surface of a container body includes a cyclic olefin copolymer, and a diameter upstream of an outlet of the container body ranges from 0.5 mm to 8.0 mm.

IPC Classes  ?

76.

HADALABO

      
Application Number 1688558
Status Registered
Filing Date 2022-08-24
Registration Date 2022-08-24
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations

Goods & Services

Cosmetics; beauty care cosmetics; cosmetic preparations for slimming purposes; beauty serums; cosmetic kits; facial preparations (cosmetic); cosmetic preparations for skin care; aloe vera preparations for cosmetic purposes; make-up; fair complexion cream; skin whitening creams; beauty masks; skin lotions; hair lotions; body lotion; hair care creams; hair nourishers [for cosmetic use]; hair moisturizers; make-up powder; milk for cosmetic purposes; cosmetic creams; lipsticks; moisturizers; facial concealer; lip glosses; tissues impregnated with cosmetic lotions; non-medicated cosmetics for acnes; astringents for cosmetic purposes; lotions for cosmetic purposes; breath freshening sprays; breath freshening strips; breath freshening preparations; make-up removing creams; make-up removing preparations; cleansing milk for toilet purposes; cosmetic cleansing oil; deodorants for personal use; preparations for setting hair; hair tonics [cosmetics]; hand creams; lip balm; spot removal cream; baby lotion; baby powder; after sun moisturizers; sunscreen preparations; antiperspirants [toiletries]; shaving creams; cotton sticks for cosmetic purposes; hair dyes; depilatories; false nails; false eyelashes; adhesives for affixing false eyelashes; adhesives for cosmetic purposes; adhesives for affixing false hair; paint stripping preparations; shampoos; soap; mouth washes, not for medical purposes; deodorants for human beings or for animals; soaps for cosmetic purposes; cleansers for intimate personal hygiene purposes, non-medicated; antiperspirant soap; eye-washes, not for medical purposes; deodorant soap; body washes; facial washes; non-medicinal acne soap; hand soap; bath preparations, not for medical purposes; cosmetic preparations for bath; bath foam; bath salts, not for medical purposes; dentifrices; perfume and flavour materials; fragrances; room fragrancing preparations; air fragrancing preparations; incense; ethereal oils; aromatherapy oils [for cosmetic use]; massage oils; laundry preparations; laundry bleach; fabric softeners for laundry use; laundry starch; cleaning and polishing preparations; cloths impregnated with a detergent for cleaning; antistatic preparations for household purposes; de-greasing preparations for household purposes; rust removing preparations; abrasive cloth and paper; creams for leather; furniture polishes; shoe polish and creams; polishing wax.

77.

CLEANING COMPOSITION

      
Application Number JP2022013009
Publication Number 2022/202766
Status In Force
Filing Date 2022-03-22
Publication Date 2022-09-29
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Phan, Phat Thanh

Abstract

The present invention provides a cleaning composition which has excellent formulation stability. A cleaning composition which contains (A) an N-acylamino acid salt, (B) an amphoteric surfactant and (C) a polyoxyethylene polyoxypropylene glycol. A cleaning composition which contains (A) an N-acylamino acid salt (excluding an N-acylalkyl taurine salt) and (a) an N-acylalkyl taurine salt, wherein: the mass ratio of the component (a) to the component (A), namely (a)/(A) is 0.5 or more; and the pH thereof is 4.0 to 5.0. A cleaning composition which contains (A) an N-acylamino acid salt (excluding an N-acylalkyl taurine salt), (a) an N-acylalkyl taurine salt and (B) an amphoteric surfactant, wherein: the mass ratio of the component (a) to the component (A), namely (a)/(A) is less than 0.5; and the pH thereof is 4.0 to 5.0.

IPC Classes  ?

  • A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
  • A61K 8/86 - Polyethers
  • A61Q 5/02 - Preparations for cleaning the hair
  • A61Q 19/10 - Washing or bathing preparations

78.

COMPOSITION FOR EXTERNAL APPLICATION

      
Application Number 17626106
Status Pending
Filing Date 2020-08-31
First Publication Date 2022-09-15
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor Inoue, Shota

Abstract

A topical composition comprises (A) at least one polyhydric alcohol having a molecular weight of 100 to 200, and (B) at least one non-polymerizable cationic compound. The component (B) may be a compound containing a metal to be a divalent or higher cation in an aqueous solution, a basic amino acid, alkanol amine, or alkyl amine, and the component (A) may be glucose, sorbitol, fructose, xylitol, or erythritol.

IPC Classes  ?

  • A61K 8/34 - Alcohols
  • A61Q 15/00 - Anti-perspirants or body deodorants
  • A61K 8/46 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
  • A61K 8/27 - ZincCompounds thereof
  • A61K 8/26 - AluminiumCompounds thereof

79.

Ophthalmic Composition for Promoting Tear Secretion

      
Application Number 17632419
Status Pending
Filing Date 2020-08-06
First Publication Date 2022-09-08
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
Inventor
  • Takai, Yoshihiro
  • Kurose, Takahiro

Abstract

The present invention relates to an ophthalmic composition for promoting tear secretion, the composition comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile or a salt thereof.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61P 27/04 - Artificial tearsIrrigation solutions

80.

PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DIABETES

      
Application Number JP2022005125
Publication Number 2022/176735
Status In Force
Filing Date 2022-02-09
Publication Date 2022-08-25
Owner
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
  • OSAKA UNIVERSITY (Japan)
Inventor
  • Kita Shunbun
  • Horitani Emi
  • Maeda Norikazu
  • Shimomura Iichiro
  • Nishida Hiroyuki

Abstract

The purpose of the present invention is to provide a prophylactic and/or therapeutic agent for diabetes that exerts excellent effects on diabetes occurring as a side effect of the administration of an immune checkpoint inhibitor and that can also achieve certain effects on many patients. The present invention pertains to a diabetes therapeutic agent containing mesenchymal stem cells. The prophylactic and/or therapeutic agent for diabetes according to the present invention is appropriately usable particularly for diabetes caused by an immune checkpoint inhibitor and diabetes caused by anti-PD-1 antibody or anti-PD-L1 antibody.

IPC Classes  ?

  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
  • A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

81.

MESENCHYMAL STEM CELLS, ANTI-INFLAMMATORY AGENT AND THERAPEUTIC AGENT FOR NEUROLOGICAL DISEASES

      
Application Number JP2022000658
Publication Number 2022/153996
Status In Force
Filing Date 2022-01-12
Publication Date 2022-07-21
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kurogi Hikari
  • Arya Smriti
  • Choi Ka Ming

Abstract

Under these circumstances, the purpose of the present invention is to provide a novel anti-inflammatory agent and a novel therapeutic agent for neurological diseases using mesenchymal stem cells. The present invention pertains to mesenchymal stem cells characterized by hyperexpressing SIRT1. The present invention also involves mesenchymal stem cells characterized by hyperexpressing BDNF. Moreover, the present invention involves an anti-inflammatory agent and a therapeutic agent for neurological diseases comprising these cells.

IPC Classes  ?

  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 37/02 - Immunomodulators
  • C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
  • C12N 15/12 - Genes encoding animal proteins
  • C12N 15/55 - Hydrolases (3)

82.

EYEDROPS FOR INHIBITING MYOPIA PROGRESSION IN CHILDREN AND SCREENING METHOD FOR INHIBITOR OF MYOPIA PROGRESSION IN CHILDREN

      
Application Number JP2021032067
Publication Number 2022/123836
Status In Force
Filing Date 2021-09-01
Publication Date 2022-06-16
Owner
  • TSUBOTA LABORATORY, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Tsubota Kazuo
  • Kurihara Toshihide
  • Ikeda Shinichi
  • Mori Kiwako
  • Jiang Xiaoyan

Abstract

[Problem] To provide: a screening method for searching for an ingredient that inhibits PERK (PKPK-like endoplasmic reticulum kinase) pathway and/or ATF6 (activating transcription factor 6) pathway; and eyedrops and a composition comprising an active ingredient that inhibits myopia progression in children without inhibiting normal ocular growth (emmetropization), said active ingredient being obtained by the aforesaid screening method. [Solution] Eyedrops for inhibiting myopia progression in children, said eyedrops comprising, as an active ingredient, an inhibitor of PERK pathway and/or ATF6 pathway. A screening method for an inhibitor of myopia progression in children, said screening method comprising a step for bringing candidate substances into contact with eye-derived cells and a step for selecting a candidate substance using changes in a protein and/or a gene in PERK and/or ATF6 signaling pathways in the cells as an indicator.

IPC Classes  ?

  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/15 - Medicinal preparations
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

83.

EYEDROPS FOR TREATING SCLERAL THINNING AND SCREENING METHOD FOR THERAPEUTIC AGENT OF SCLERAL THINNING

      
Application Number JP2021032068
Publication Number 2022/123837
Status In Force
Filing Date 2021-09-01
Publication Date 2022-06-16
Owner
  • TSUBOTA LABORATORY, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Tsubota Kazuo
  • Kurihara Toshihide
  • Ikeda Shinichi
  • Mori Kiwako
  • Jiang Xiaoyan

Abstract

[Problem] To provide: a screening method for searching for an ingredient that inhibits and treats scleral thinning; and eyedrops that comprise an active ingredient, said active ingredient being obtained by the screening method, and thus that can inhibit excessive scleral thinning to thereby treat posterior ocular disease associated with scleral thinning. [Solution] Eyedrops that comprise, as an active ingredient, an ingredient capable of simultaneously inhibiting PERK pathway and/or ATF6 pathway. A screening method for an ingredient capable of simultaneously inhibiting PERK pathway and/or ATF6 pathway, said screening method comprising a step for bringing candidate substances into contact with eye-derived cells and a step for selecting a candidate substance using effects on scleral thinning in the cells as an indicator.

IPC Classes  ?

  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61K 9/08 - Solutions
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
  • A61P 27/02 - Ophthalmic agents
  • A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia
  • C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G01N 33/15 - Medicinal preparations
  • G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

84.

TOPICAL COMPOSITION

      
Document Number 03137312
Status In Force
Filing Date 2021-11-01
Open to Public Date 2022-05-05
Grant Date 2023-08-01
Owner
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
  • THE MENTHOLATUM COMPANY (USA)
Inventor
  • Kawaguchi, Yoshiaki
  • Alama, Tammam

Abstract

Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

IPC Classes  ?

  • A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
  • A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
  • A61P 31/10 - Antimycotics

85.

Topical composition

      
Application Number 17498147
Grant Number 12090133
Status In Force
Filing Date 2021-10-11
First Publication Date 2022-05-05
Grant Date 2024-09-17
Owner
  • THE MENTHOLATUM COMPANY (USA)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kawaguchi, Yoshiaki
  • Alama, Tammam

Abstract

Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

IPC Classes  ?

  • A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/06 - OintmentsBases therefor

86.

MELANO CC

      
Application Number 217885100
Status Pending
Filing Date 2022-04-13
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations

Goods & Services

(1) Cosmetics; beauty care preparations; cosmetic preparations for slimming purposes; beauty serums; cosmetic kits; facial preparations (cosmetic); facial cleansers; cosmetic preparations for skin care; aloe vera preparations for cosmetic purposes; make-up preparations; skin whitening creams; beauty masks; skin lotions; hair lotions; body lotion; hair care creams; hair nourishers [for cosmetic use]; hair moisturizers; face powder; milk for cosmetic purposes; cosmetic creams; lipsticks; moisturizers; facial concealer; lip glosses; tissues impregnated with cosmetic lotions; non-medicated cosmetics for acnes; astringents for cosmetic purposes; lotions for cosmetic purposes; breath freshening sprays; breath freshening strips; breath freshening preparations; make-up removing creams; make-up removing preparations; cleansing milk for toilet purposes; body deodorants [perfumery]; hair setting preparations; hair tonics [cosmetics]; hand creams; lip balm; spot removal cream; baby lotion; baby powder; after sun moisturizers; sunscreen preparations; anti-perspirants; shaving creams; cotton sticks for cosmetic purposes; hair coloring preparations; depilatories; false nails; false eyelashes; adhesives for affixing false eyelashes; adhesives for cosmetic purposes; adhesives for affixing false hair; paint stripping preparations; shampoos; soap; mouth washes, not for medical purposes; deodorants for human beings or for animals; soaps for cosmetic purposes; cleansers for intimate personal hygiene purposes, non-medicated; antiperspirant soap; eye-washes, not for medical purposes; deodorant soap; body washes; facial washes; non-medicated soap for acnes; hand soap; bath preparations, not for medical purposes; cosmetic preparations for bath; bath foam; bath salts, non-medicated; dentifrices; fragrances; room fragrances; air fragrancing preparations; incense; essential oils; aromatherapy oils [for cosmetic use]; massage oil; laundry preparations; laundry bleach; fabric softeners for laundry use; laundry starch; cleaning and polishing preparations; cloths; impregnated with a detergent for cleaning; antistatic preparations for household purposes; degreasers other than for use in manufacturing processes; rust removing preparations; abrasive cloth and paper; creams for leather; furniture polish; shoe polish and creams; polishing wax

87.

MELANO CC

      
Application Number 018687128
Status Registered
Filing Date 2022-04-13
Registration Date 2022-08-19
Owner ROHTO Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations

Goods & Services

Cosmetics; Beauty care preparations; Cosmetic preparations for slimming purposes; Beauty serums; Cosmetic kits; Facial preparations (cosmetic); Facial cleansers; Cosmetic preparations for skin care; Aloe vera preparations for cosmetic purposes; Make-up preparations; Skin whitening creams; Beauty masks; Skin lotions; Hair lotions; Body lotion; Hair care creams; Hair nourishers [for cosmetic use]; Hair moisturizers; Face powder; Milk for cosmetic purposes; Cosmetic creams; Lipsticks; Moisturizers; Facial concealer; Lip glosses; Tissues impregnated with cosmetic lotions; Non-medicated cosmetics for acnes; Astringents for cosmetic purposes; Lotions for cosmetic purposes; Breath freshening sprays; Breath freshening strips; Breath freshening preparations; Make-up removing creams; Make-up removing preparations; Cleansing milk for toilet purposes; Body deodorants [perfumery]; Hair setting preparations; Hair tonics [cosmetics]; Hand creams; Lip balm; Spot removal cream; Baby lotion; Baby powder; After sun moisturizers; Sunscreen preparations; Anti-perspirants; Shaving creams; Cotton sticks for cosmetic purposes; Hair coloring preparations; Depilatories; False nails; False eyelashes; Adhesives for affixing false eyelashes; Adhesives for cosmetic purposes; Adhesives for affixing false hair; Paint stripping preparations; Shampoos; Soap; Mouth washes, not for medical purposes; Deodorants for human beings or for animals; Soaps for cosmetic purposes; Cleansers for intimate personal hygiene purposes, non-medicated; Antiperspirant soap; Eye-washes, not for medical purposes; Deodorant soap; Body washes; Facial washes; Non-medicated soap for acnes; Hand soap; Bath preparations, not for medical purposes; Cosmetic preparations for bath; Bath foam; Bath salts, non-medicated; Dentifrices; Fragrances; Room fragrances; Air fragrancing preparations; Incense; Essential oils; Aromatherapy oils [for cosmetic use]; Massage oil; Laundry preparations; Laundry bleach; Fabric softeners for laundry use; Laundry starch; Cleaning and polishing preparations; Cloths impregnated with a detergent for cleaning; Antistatic preparations for household purposes; Degreasers other than for use in manufacturing processes; Rust removing preparations; Abrasive cloth and paper; Creams for leather; Furniture polish; Shoe polish and creams; Polishing wax.

88.

COMPOSITION FOR EXTERNAL USE ON SKIN

      
Application Number JP2021032069
Publication Number 2022/050295
Status In Force
Filing Date 2021-09-01
Publication Date 2022-03-10
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Nishimoto,airi

Abstract

Provided is a composition for external use on skin, which can be packed in a container easily in the production thereof and is configured such that a proper amount can be discharged upon the application onto the skin. A composition for external use on skin is produced, which has good wettability on a polyolefin resin. The composition for external use on skin is prepared, the composition for external use on skin comprising (A) at least one component selected from the group consisting of ascorbic acid and an ascorbic acid salt and (B) a lower alcohol, and the composition for external use on skin being packed in a container in which a portion or the whole of a face that comes into contact with the composition for external use on skin comprises a resin containing a polyolefin.

IPC Classes  ?

89.

COMPOSITION FOR AMELIORATING UNPLEASANT STATE CAUSED BY MENSTRUATION

      
Application Number JP2021031219
Publication Number 2022/045211
Status In Force
Filing Date 2021-08-25
Publication Date 2022-03-03
Owner
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japan)
  • LINK GENOMICS, INC. (Japan)
  • ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Katabuchi,hidetaka
  • Honda,ritsuo
  • Niwa,shinichiro
  • Kitadai,eri
  • Hayashi,hidemi
  • Arita,harumasa

Abstract

The purpose of the present invention is to provide: a composition for ameliorating an unpleasant state related to menstruation, the composition being effective for an unpleasant feeling felt by females from first menstruation to menopause, in particular, a very unpleasant feeling felt by young females, having anti-EMT activity, and being sufficiently experienced as foodstuff; and a functional food containing said composition. According to the present invention, a composition, which is for ameliorating an unpleasant state caused by menstruation and contains at least one selected from the group consisting of black rice, cherry, and extracts thereof, is prepared.

IPC Classes  ?

  • A61K 36/899 - Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
  • A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
  • A61K 36/736 - Prunus, e.g. plum, cherry, peach, apricot or almond
  • A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
  • A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
  • A61P 1/12 - Antidiarrhoeals
  • A61P 3/02 - Nutrients, e.g. vitamins, minerals
  • A61P 7/06 - Antianaemics
  • A61P 15/00 - Drugs for genital or sexual disordersContraceptives
  • A61P 25/00 - Drugs for disorders of the nervous system
  • A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

90.

Topical composition containing ascorbic acid and/or salt thereof

      
Application Number 17279296
Grant Number 12296038
Status In Force
Filing Date 2019-09-25
First Publication Date 2022-02-03
Grant Date 2025-05-13
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kitaoka, Yu
  • Iwai, Mariko
  • Yamashina, Sho

Abstract

Provided is a very stable topical composition. A topical composition is prepared that contains (A) from 1 to 40% by mass of at least one type selected from the group consisting of ascorbic acid and salts of ascorbic acid; (B) at least 20% by mass of a diol having three carbon atoms; (C) at least one type selected from the group consisting of tocopherol, salts of tocopherol, and derivatives of tocopherol; and (D) water, wherein the mass ratio of component (D) to component (A) is from 0.5 to 5.0 and the topical composition includes less than 20% by mass of glycol ether.

IPC Classes  ?

91.

AQUEOUS COMPOSITION

      
Document Number 03190310
Status Pending
Filing Date 2021-07-30
Open to Public Date 2022-02-03
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kubo, Ozora
  • Hayashi, Saeko
  • Kita, Akiko

Abstract

The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of citric acid, phosphoric acid, and salts of these.

IPC Classes  ?

  • A61K 9/08 - Solutions
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 47/04 - Non-metalsCompounds thereof
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • A61P 27/02 - Ophthalmic agents

92.

AQUEOUS COMPOSITION

      
Document Number 03190313
Status Pending
Filing Date 2021-07-30
Open to Public Date 2022-02-03
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kubo, Ozora
  • Hayashi, Saeko
  • Kita, Akiko

Abstract

The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of edetic acid, creatinine, and salts of these.

IPC Classes  ?

  • A61K 9/08 - Solutions
  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61P 27/02 - Ophthalmic agents

93.

AQUEOUS COMPOSITION

      
Application Number JP2021028439
Publication Number 2022/025279
Status In Force
Filing Date 2021-07-30
Publication Date 2022-02-03
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kubo Ozora
  • Hayashi Saeko
  • Kita Akiko

Abstract

The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of citric acid, phosphoric acid, and salts of these.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 9/08 - Solutions
  • A61K 47/04 - Non-metalsCompounds thereof
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • A61P 27/02 - Ophthalmic agents

94.

AQUEOUS COMPOSITION

      
Application Number JP2021028441
Publication Number 2022/025281
Status In Force
Filing Date 2021-07-30
Publication Date 2022-02-03
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Kubo Ozora
  • Hayashi Saeko
  • Kita Akiko

Abstract

The present invention relates to an aqueous composition containing (A) delgocitinib or a salt thereof and (B) at least one substance selected from the group consisting of edetic acid, creatinine, and salts of these.

IPC Classes  ?

  • A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 9/08 - Solutions
  • A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
  • A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
  • A61P 27/02 - Ophthalmic agents

95.

RN

      
Application Number 1637129
Status Registered
Filing Date 2021-09-08
Registration Date 2021-09-08
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

In-vitro diagnostic drugs; eye wash bactericides; eye ointments; contact lens cleaning preparations; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; reagent paper for medical purposes; collyrium; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements (excluding those belonging to drugs); oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for humans; semen for artificial insemination.

96.

COMPOSITION FOR EXTERNAL USE

      
Application Number JP2021024951
Publication Number 2022/004843
Status In Force
Filing Date 2021-07-01
Publication Date 2022-01-06
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Inoue,shota
  • Marukawa,junko

Abstract

The purpose of the present invention is to provide a composition which, even if the ethanol content is relatively high, suppresses ethanol-induced drying that could occur upon application onto the skin, and which, when used, gives a good feeling. Provided is a composition for external use, which contains (A) ethanol and (B) at least one selected from the group consisting of erythritol, sorbitol, and xylitol, and has an ethanol (A) content of 32 to 85 mass%.

IPC Classes  ?

  • A61K 8/34 - Alcohols
  • A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
  • A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
  • A61P 17/00 - Drugs for dermatological disorders
  • A61P 31/02 - Local antiseptics
  • A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q 19/00 - Preparations for care of the skin

97.

COMPOSITION FOR EXTERNAL USE ON SKIN CONTAINING ASCORBIC ACID AND/OR SALT THEREOF

      
Application Number JP2021023237
Publication Number 2021/256566
Status In Force
Filing Date 2021-06-18
Publication Date 2021-12-23
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ando,tatsuya
  • Masumoto,ai
  • Nakada,taiki

Abstract

Provided is a composition for external use on the skin which is excellent in terms of use feeling and appearance. The purpose of the present invention is to provide a composition for external use on the skin which has satisfactory use feeling, that is, good slipperiness, and is reduced in coloration. The composition for external use on the skin comprises (A) at least one compound selected from the group consisting of ascorbic acid and salts of ascorbic acid, (B) at least one compound selected from the group consisting of salicylic acid, salts of salicylic acid, and derivatives of salicylic acid, and (C) a diol having three carbon atoms, the content of which is 1-50 mass%.

IPC Classes  ?

  • A61P 43/00 - Drugs for specific purposes, not provided for in groups
  • A61P 17/00 - Drugs for dermatological disorders
  • A61P 17/10 - Anti-acne agents
  • A61P 17/16 - Emollients or protectives, e.g. against radiation
  • A61P 17/18 - Antioxidants, e.g. antiradicals
  • A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
  • A61Q 19/00 - Preparations for care of the skin
  • A61K 8/34 - Alcohols
  • A61K 8/368 - Carboxylic acidsSalts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
  • A61K 8/67 - Vitamins
  • A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
  • A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
  • C07D 307/62 - Three oxygen atoms, e.g. ascorbic acid
  • A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof

98.

ROHTONITTEN

      
Application Number 1633101
Status Registered
Filing Date 2021-09-08
Registration Date 2021-09-08
Owner Rohto Pharmaceutical Co., Ltd. (Japan)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

In-vitro diagnostic drugs; eye wash bactericides; eye ointments; contact lens cleaning preparations; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; reagent paper for medical purposes; collyrium; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; dietary supplements (excluding those belonging to drugs); oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; dietary supplements for humans; semen for artificial insemination.

99.

OIL-IN-WATER COSMETIC COMPOSITION

      
Application Number JP2021019755
Publication Number 2021/241559
Status In Force
Filing Date 2021-05-25
Publication Date 2021-12-02
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor Kojima,ami

Abstract

The present invention provides an oil-in-water cosmetic composition. The present invention is an oil-in-water cosmetic composition which contains (A) a benzotriazole type ultraviolet absorbent, (B) one or more substances that are selected from the group consisting of silicone waxes and silica, and (C) water. With respect to this oil-in-water cosmetic composition, the average particle diameter of silica in the component (B) is 1 μm or more; and the content of the component (C) based on the total amount of this oil-in-water cosmetic composition is 50% by mass or more.

IPC Classes  ?

  • A61Q 1/02 - Preparations containing skin colorants, e.g. pigments
  • A61Q 1/12 - Face or body powders, e.g. for grooming, adorning or absorbing
  • A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
  • A61K 8/06 - Emulsions
  • A61K 8/25 - SiliconCompounds thereof
  • A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K 8/895 - Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone

100.

OPHTHALMIC COMPOSITION

      
Application Number JP2021014059
Publication Number 2021/220712
Status In Force
Filing Date 2021-03-31
Publication Date 2021-11-04
Owner ROHTO PHARMACEUTICAL CO., LTD. (Japan)
Inventor
  • Ando Tatsuya
  • Mitsuguchi Yoko
  • Matsumoto Sachiko
  • Nakata Atsuko

Abstract

The present invention relates to an ophthalmic composition for suppressing drying of the eyes, the composition containing at least one substance selected from the group consisting of chondroitin sulfates having weight-average molecular weights of 30,000 to 50,000 and salts thereof.

IPC Classes  ?

  • A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
  • A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61P 27/04 - Artificial tearsIrrigation solutions
  1     2     3     4        Next Page